Lv1
8 积分 2026-01-08 加入
Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
1个月前
已完结
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial
1个月前
已完结
Therapeutic advances in chronic lymphocytic leukemia: A focus on molecular pathogenesis, targeted therapies, and supportive care
1个月前
已完结
Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial
1个月前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
1个月前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
1个月前
已完结
The phenotypic spectrum of YWHAG ‐related epilepsy: From mild febrile seizures to severe developmental delay and epileptic encephalopathy
1个月前
已完结
Genotypic spectrum in 1215 patients with Dravet syndrome or Dravet syndrome-like phenotype
1个月前
已完结
Somatic variants in SLC35A2 leading to defects in N-glycosylation in mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE)
1个月前
已完结
Incidence of Cardiovascular Events and Carotid Artery USG Abnormalities in Chronic Myeloid Leukemia Patients on Nilotinib Therapy: A 20-Year Single-Center Study
1个月前
已完结
皖公网安备34019202002308
